{"title":"Biosimilar Antibodies","description":"Research-grade recombinant biosimilar antibodies and receptor-trap proteins that reproduce the binding specificity of reference biologic drugs — for use as binding reagents, functional blocking tools, and PK\/ADA assay controls. For Research Use Only.","products":[{"product_id":"eculizumab-biosimilar-research-grade-bha18300148","title":"Eculizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eEculizumab\u003c\/strong\u003e. Like the reference molecule, it binds complement component C5 and blocks its cleavage into C5a and C5b, inhibiting formation of the terminal complement complex (C5b-9). It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Eculizumab and therefore targets \u003cstrong\u003eComplement C5\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eComplement C5\u003c\/strong\u003e. The molecule binds complement component C5 and blocks its cleavage into C5a and C5b, inhibiting formation of the terminal complement complex (C5b-9).\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against Complement C5; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of Complement C5 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to Complement C5.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Eculizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eEculizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eComplement C5\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG2\/4κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of Complement C5 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Eculizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327958704493,"sku":"ab-131-eculizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_1e8e0070-9c44-4ed5-aee5-c78f459be7a5.jpg?v=1778728448"},{"product_id":"alemtuzumab-biosimilar-research-grade-bha18300145","title":"Alemtuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAlemtuzumab\u003c\/strong\u003e. Like the reference molecule, it binds CD52 on the surface of lymphocytes and mediates antibody-dependent cell lysis and lymphocyte depletion. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Alemtuzumab and therefore targets \u003cstrong\u003eCD52\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD52\u003c\/strong\u003e. The molecule binds CD52 on the surface of lymphocytes and mediates antibody-dependent cell lysis and lymphocyte depletion.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD52; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD52 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD52.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD52 on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Alemtuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAlemtuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD52\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD52 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Alemtuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327959425389,"sku":"ab-131-alemtuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_95fbfd0a-adb7-4c81-a451-c3fb6398886b.jpg?v=1778728442"},{"product_id":"bevacizumab-biosimilar-research-grade-bha18300146","title":"Bevacizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eBevacizumab\u003c\/strong\u003e. Like the reference molecule, it binds and neutralizes vascular endothelial growth factor A (VEGF-A), blocking VEGF receptor activation and angiogenesis. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Bevacizumab and therefore targets \u003cstrong\u003eVEGF-A\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eVEGF-A\u003c\/strong\u003e. The molecule binds and neutralizes vascular endothelial growth factor A (VEGF-A), blocking VEGF receptor activation and angiogenesis.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against VEGF-A; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of VEGF-A in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to VEGF-A.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Bevacizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eBevacizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eVEGF-A\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of VEGF-A binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Bevacizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327959753069,"sku":"ab-131-bevacizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_13863ba4-2f88-424a-b51e-d3e4e7757461.jpg?v=1778728442"},{"product_id":"infliximab-biosimilar-research-grade-bha18300149","title":"Infliximab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eChimeric monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eInfliximab\u003c\/strong\u003e. Like the reference molecule, it binds soluble and transmembrane TNF-α and neutralizes its pro-inflammatory signaling. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Infliximab and therefore targets \u003cstrong\u003eTNF-α\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eTNF-α\u003c\/strong\u003e. The molecule binds soluble and transmembrane TNF-α and neutralizes its pro-inflammatory signaling.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against TNF-α; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of TNF-α in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to TNF-α.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Infliximab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eInfliximab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eChimeric monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eTNF-α\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of TNF-α binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Infliximab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327959982445,"sku":"ab-131-infliximab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_799f3117-df0f-4a15-816c-18e38943fe50.jpg?v=1778728448"},{"product_id":"cetuximab-biosimilar-research-grade-bha18300147","title":"Cetuximab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eChimeric monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eCetuximab\u003c\/strong\u003e. Like the reference molecule, it binds the extracellular domain of EGFR and blocks ligand binding and receptor activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Cetuximab and therefore targets \u003cstrong\u003eEGFR (HER1)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eEGFR (HER1)\u003c\/strong\u003e. The molecule binds the extracellular domain of EGFR and blocks ligand binding and receptor activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against EGFR (HER1); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of EGFR (HER1) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to EGFR (HER1).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface EGFR (HER1) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Cetuximab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eCetuximab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eChimeric monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eEGFR (HER1)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of EGFR (HER1) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Cetuximab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327960375661,"sku":"ab-131-cetuximab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_17424d1a-f444-4b3a-bde5-ba01fa5a0ec4.jpg?v=1778728445"},{"product_id":"adalimumab-biosimilar-research-grade-bha18300144","title":"Adalimumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAdalimumab\u003c\/strong\u003e. Like the reference molecule, it binds and neutralizes soluble and transmembrane TNF-α. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Adalimumab and therefore targets \u003cstrong\u003eTNF-α\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eTNF-α\u003c\/strong\u003e. The molecule binds and neutralizes soluble and transmembrane TNF-α.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against TNF-α; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of TNF-α in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to TNF-α.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Adalimumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAdalimumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eTNF-α\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of TNF-α binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Adalimumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327960768877,"sku":"ab-131-adalimumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_d2f19b4a-d227-4876-90b0-80bf02bb5dfc.jpg?v=1778728447"},{"product_id":"matuzumab-biosimilar-research-grade-bha18300150","title":"Matuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eMatuzumab\u003c\/strong\u003e. Like the reference molecule, it binds EGFR and blocks ligand-induced receptor activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Matuzumab and therefore targets \u003cstrong\u003eEGFR\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eEGFR\u003c\/strong\u003e. The molecule binds EGFR and blocks ligand-induced receptor activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against EGFR; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of EGFR in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to EGFR.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface EGFR on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Matuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eMatuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of EGFR binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Matuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961489773,"sku":"ab-131-matuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_44d727ee-5250-4165-9a7c-949e8fac052e.jpg?v=1778728453"},{"product_id":"rituximab-biosimilar-research-grade-bha18300154","title":"Rituximab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eChimeric monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eRituximab\u003c\/strong\u003e. Like the reference molecule, it binds CD20 on B cells and triggers complement-dependent and antibody-dependent B-cell depletion. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Rituximab and therefore targets \u003cstrong\u003eCD20\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD20\u003c\/strong\u003e. The molecule binds CD20 on B cells and triggers complement-dependent and antibody-dependent B-cell depletion.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD20; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD20 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD20.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD20 on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Rituximab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eRituximab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eChimeric monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD20\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD20 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Rituximab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961719149,"sku":"ab-131-rituximab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_62861a91-aeec-43f3-bf6f-3029db77c7b4.jpg?v=1778728454"},{"product_id":"avelumab-biosimilar-research-grade-bha18300160","title":"Avelumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAvelumab\u003c\/strong\u003e. Like the reference molecule, it binds PD-L1 and blocks its interaction with PD-1; retains ADCC activity. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Avelumab and therefore targets \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e. The molecule binds PD-L1 and blocks its interaction with PD-1; retains ADCC activity.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PD-L1 (CD274); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PD-L1 (CD274) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PD-L1 (CD274).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface PD-L1 (CD274) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Avelumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAvelumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePD-L1 (CD274)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1λ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PD-L1 (CD274) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Avelumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961817453,"sku":"ab-131-avelumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_3695d9fe-197e-45f0-8189-8532cb6828c4.jpg?v=1778728455"},{"product_id":"denosumab-biosimilar-research-grade-bha18300162","title":"Denosumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eDenosumab\u003c\/strong\u003e. Like the reference molecule, it binds RANKL and prevents RANK activation, inhibiting osteoclast differentiation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Denosumab and therefore targets \u003cstrong\u003eRANKL (TNFSF11)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eRANKL (TNFSF11)\u003c\/strong\u003e. The molecule binds RANKL and prevents RANK activation, inhibiting osteoclast differentiation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against RANKL (TNFSF11); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of RANKL (TNFSF11) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to RANKL (TNFSF11).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Denosumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eDenosumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eRANKL (TNFSF11)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG2\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of RANKL (TNFSF11) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Denosumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961784685,"sku":"ab-131-denosumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_fcc0126f-72f8-4697-9e3d-ee81f89538c1.jpg?v=1778728455"},{"product_id":"ipilimumab-biosimilar-research-grade-bha18300166","title":"Ipilimumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eIpilimumab\u003c\/strong\u003e. Like the reference molecule, it binds CTLA-4 and blocks its interaction with CD80\/CD86, enhancing T-cell activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ipilimumab and therefore targets \u003cstrong\u003eCTLA-4 (CD152)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCTLA-4 (CD152)\u003c\/strong\u003e. The molecule binds CTLA-4 and blocks its interaction with CD80\/CD86, enhancing T-cell activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CTLA-4 (CD152); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CTLA-4 (CD152) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CTLA-4 (CD152).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CTLA-4 (CD152) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ipilimumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eIpilimumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCTLA-4 (CD152)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CTLA-4 (CD152) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ipilimumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961882989,"sku":"ab-131-ipilimumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_6c85ec3e-60ca-4851-b6f8-72c9f77198a7.jpg?v=1778728456"},{"product_id":"nivolumab-biosimilar-research-grade-bha18300152","title":"Nivolumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eNivolumab\u003c\/strong\u003e. Like the reference molecule, it binds PD-1 and blocks PD-L1\/PD-L2 engagement, restoring T-cell activity. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Nivolumab and therefore targets \u003cstrong\u003ePD-1 (CD279)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePD-1 (CD279)\u003c\/strong\u003e. The molecule binds PD-1 and blocks PD-L1\/PD-L2 engagement, restoring T-cell activity.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PD-1 (CD279); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PD-1 (CD279) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PD-1 (CD279).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface PD-1 (CD279) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Nivolumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eNivolumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePD-1 (CD279)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG4\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PD-1 (CD279) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Nivolumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961948525,"sku":"ab-131-nivolumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_cacb43e6-4d53-4d59-9d50-a45626148ed3.jpg?v=1778728452"},{"product_id":"tocilizumab-biosimilar-research-grade-bha18300155","title":"Tocilizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eTocilizumab\u003c\/strong\u003e. Like the reference molecule, it binds membrane-bound and soluble IL-6R and blocks IL-6 signaling. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Tocilizumab and therefore targets \u003cstrong\u003eIL-6 receptor (IL-6R)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eIL-6 receptor (IL-6R)\u003c\/strong\u003e. The molecule binds membrane-bound and soluble IL-6R and blocks IL-6 signaling.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against IL-6 receptor (IL-6R); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of IL-6 receptor (IL-6R) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to IL-6 receptor (IL-6R).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface IL-6 receptor (IL-6R) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Tocilizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eTocilizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eIL-6 receptor (IL-6R)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of IL-6 receptor (IL-6R) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Tocilizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327961981293,"sku":"ab-131-tocilizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_8da5eaea-ac36-48ef-b92f-f2277da3f4fb.jpg?v=1778728453"},{"product_id":"omalizumab-biosimilar-research-grade-bha18300153","title":"Omalizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eOmalizumab\u003c\/strong\u003e. Like the reference molecule, it binds the Cε3 domain of free human IgE and prevents IgE binding to the FcεRI receptor. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Omalizumab and therefore targets \u003cstrong\u003eHuman IgE (Cε3 domain)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHuman IgE (Cε3 domain)\u003c\/strong\u003e. The molecule binds the Cε3 domain of free human IgE and prevents IgE binding to the FcεRI receptor.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against Human IgE (Cε3 domain); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of Human IgE (Cε3 domain) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to Human IgE (Cε3 domain).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Omalizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eOmalizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHuman IgE (Cε3 domain)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of Human IgE (Cε3 domain) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Omalizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962014061,"sku":"ab-131-omalizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_dfce8b46-4e57-46d6-9777-2b8e2b7753cc.jpg?v=1778728452"},{"product_id":"alirocumab-biosimilar-research-grade-bha18300159","title":"Alirocumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAlirocumab\u003c\/strong\u003e. Like the reference molecule, it binds PCSK9 and blocks its interaction with the LDL receptor. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Alirocumab and therefore targets \u003cstrong\u003ePCSK9\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePCSK9\u003c\/strong\u003e. The molecule binds PCSK9 and blocks its interaction with the LDL receptor.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PCSK9; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PCSK9 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PCSK9.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Alirocumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAlirocumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePCSK9\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PCSK9 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Alirocumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962046829,"sku":"ab-131-alirocumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_b2d9ad05-96d4-4000-99d7-5b0222458b1c.jpg?v=1778728455"},{"product_id":"pertuzumab-biosimilar-research-grade-bha18300171","title":"Pertuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003ePertuzumab\u003c\/strong\u003e. Like the reference molecule, it binds HER2 subdomain II and blocks HER2–HER3 heterodimerization. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Pertuzumab and therefore targets \u003cstrong\u003eHER2 (ERBB2), dimerization domain II\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHER2 (ERBB2), dimerization domain II\u003c\/strong\u003e. The molecule binds HER2 subdomain II and blocks HER2–HER3 heterodimerization.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against HER2 (ERBB2), dimerization domain II; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of HER2 (ERBB2), dimerization domain II in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to HER2 (ERBB2), dimerization domain II.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface HER2 (ERBB2), dimerization domain II on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Pertuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003ePertuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHER2 (ERBB2), dimerization domain II\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of HER2 (ERBB2), dimerization domain II binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Pertuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962079597,"sku":"ab-131-pertuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_2810e90d-5831-4893-a7be-4159a897fa1b.jpg?v=1778728454"},{"product_id":"etanercept-biosimilar-research-grade-bha18300164","title":"Etanercept Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eFc-fusion protein\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis research-grade reagent reproduces the target specificity of the reference biologic \u003cstrong\u003eEtanercept\u003c\/strong\u003e. It is a soluble dimeric TNF receptor that binds and neutralizes TNF-α and lymphotoxin-α. Supplied for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional control and assay standard.\u003c\/p\u003e\n  \u003cp\u003e\u003cstrong\u003eEtanercept\u003c\/strong\u003e is a fusion protein, not a monoclonal antibody; this product is the corresponding recombinant Fc-fusion protein and is provided as a research-grade equivalent.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eTNF-α \/ lymphotoxin-α\u003c\/strong\u003e. The molecule is a soluble dimeric TNF receptor that binds and neutralizes TNF-α and lymphotoxin-α.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against TNF-α \/ lymphotoxin-α; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of TNF-α \/ lymphotoxin-α in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to TNF-α \/ lymphotoxin-α.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Etanercept.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eEtanercept\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eRecombinant Fc-fusion protein (TNFR2\/p75 ectodomain – human IgG1 Fc)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eTNF-α \/ lymphotoxin-α\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003e— (not an antibody)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of TNF-α \/ lymphotoxin-α binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Etanercept drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962112365,"sku":"ab-131-etanercept","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_ed2685ad-e353-4fd8-9104-9901c32a2803.jpg?v=1778728457"},{"product_id":"trastuzumab-biosimilar-research-grade-bha18300156","title":"Trastuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eTrastuzumab\u003c\/strong\u003e. Like the reference molecule, it binds HER2 subdomain IV, inhibits HER2 signaling and mediates ADCC. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Trastuzumab and therefore targets \u003cstrong\u003eHER2 (ERBB2), domain IV\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHER2 (ERBB2), domain IV\u003c\/strong\u003e. The molecule binds HER2 subdomain IV, inhibits HER2 signaling and mediates ADCC.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against HER2 (ERBB2), domain IV; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of HER2 (ERBB2), domain IV in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to HER2 (ERBB2), domain IV.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface HER2 (ERBB2), domain IV on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Trastuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eTrastuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHER2 (ERBB2), domain IV\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of HER2 (ERBB2), domain IV binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Trastuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962145133,"sku":"ab-131-trastuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_2f322bc4-3373-45e8-9846-919978eeee36.jpg?v=1778728452"},{"product_id":"ustekinumab-biosimilar-research-grade-bha18300175","title":"Ustekinumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eUstekinumab\u003c\/strong\u003e. Like the reference molecule, it binds the shared p40 subunit of IL-12 and IL-23 and blocks their signaling. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ustekinumab and therefore targets \u003cstrong\u003eIL-12 \/ IL-23 shared p40 subunit (IL12B)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eIL-12 \/ IL-23 shared p40 subunit (IL12B)\u003c\/strong\u003e. The molecule binds the shared p40 subunit of IL-12 and IL-23 and blocks their signaling.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against IL-12 \/ IL-23 shared p40 subunit (IL12B); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of IL-12 \/ IL-23 shared p40 subunit (IL12B) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to IL-12 \/ IL-23 shared p40 subunit (IL12B).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ustekinumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eUstekinumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eIL-12 \/ IL-23 shared p40 subunit (IL12B)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of IL-12 \/ IL-23 shared p40 subunit (IL12B) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ustekinumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962177901,"sku":"ab-131-ustekinumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_2423e0a1-79b6-4f9d-b270-0cecc7d77cc8.jpg?v=1778728456"},{"product_id":"panitumumab-biosimilar-research-grade-bha18300169","title":"Panitumumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003ePanitumumab\u003c\/strong\u003e. Like the reference molecule, it binds EGFR and blocks ligand binding and receptor activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Panitumumab and therefore targets \u003cstrong\u003eEGFR\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eEGFR\u003c\/strong\u003e. The molecule binds EGFR and blocks ligand binding and receptor activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against EGFR; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of EGFR in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to EGFR.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface EGFR on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Panitumumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003ePanitumumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG2κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of EGFR binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Panitumumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962210669,"sku":"ab-131-panitumumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_920de083-7930-4d72-90af-c6a6bb5cca28.jpg?v=1778728456"},{"product_id":"ramucirumab-biosimilar-research-grade-bha18300173","title":"Ramucirumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eRamucirumab\u003c\/strong\u003e. Like the reference molecule, it binds the extracellular domain of VEGFR2 and blocks VEGF ligand binding. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ramucirumab and therefore targets \u003cstrong\u003eVEGFR2 (KDR)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eVEGFR2 (KDR)\u003c\/strong\u003e. The molecule binds the extracellular domain of VEGFR2 and blocks VEGF ligand binding.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against VEGFR2 (KDR); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of VEGFR2 (KDR) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to VEGFR2 (KDR).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface VEGFR2 (KDR) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ramucirumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eRamucirumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eVEGFR2 (KDR)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of VEGFR2 (KDR) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ramucirumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962308973,"sku":"ab-131-ramucirumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_f6e49e1b-a3d4-4ccd-afc5-8d999435464c.jpg?v=1778728457"},{"product_id":"secukinumab-biosimilar-research-grade-bha18300174","title":"Secukinumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eSecukinumab\u003c\/strong\u003e. Like the reference molecule, it binds and neutralizes the cytokine IL-17A. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Secukinumab and therefore targets \u003cstrong\u003eIL-17A\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eIL-17A\u003c\/strong\u003e. The molecule binds and neutralizes the cytokine IL-17A.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against IL-17A; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of IL-17A in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to IL-17A.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Secukinumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eSecukinumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eIL-17A\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of IL-17A binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Secukinumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962341741,"sku":"ab-131-secukinumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_c051b852-7411-463d-b4f2-5990f72a376a.jpg?v=1778728457"},{"product_id":"daratumumab-biosimilar-research-grade-bha18300163","title":"Daratumumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eDaratumumab\u003c\/strong\u003e. Like the reference molecule, it binds CD38 on plasma cells and mediates CDC, ADCC and ADCP. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Daratumumab and therefore targets \u003cstrong\u003eCD38\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD38\u003c\/strong\u003e. The molecule binds CD38 on plasma cells and mediates CDC, ADCC and ADCP.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD38; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD38 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD38.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD38 on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Daratumumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eDaratumumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD38\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD38 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Daratumumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962407277,"sku":"ab-131-daratumumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_ae28eb83-95fe-44e2-8695-caa5cd295e8e.jpg?v=1778728454"},{"product_id":"ranibizumab-biosimilar-research-grade-bha18300172","title":"Ranibizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized antibody Fab fragment\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade Fab fragment that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eRanibizumab\u003c\/strong\u003e. Like the reference molecule, it is an affinity-matured Fab fragment that binds and neutralizes VEGF-A isoforms. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ranibizumab and therefore targets \u003cstrong\u003eVEGF-A\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eVEGF-A\u003c\/strong\u003e. The molecule is an affinity-matured Fab fragment that binds and neutralizes VEGF-A isoforms.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against VEGF-A; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of VEGF-A in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to VEGF-A.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ranibizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eRanibizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized antibody Fab fragment\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eVEGF-A\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1 Fab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of VEGF-A binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ranibizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962538349,"sku":"ab-131-ranibizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_2231fb36-7a14-4e30-b209-a1390015f083.jpg?v=1778728456"},{"product_id":"ado-trastuzumab-emtansine-biosimilar-research-grade-bha18300157","title":"Ado-trastuzumab emtansine Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eAntibody–drug conjugate (trastuzumab – DM1)\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade antibody–drug conjugate that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAdo-trastuzumab emtansine\u003c\/strong\u003e. Like the reference molecule, it is a HER2-targeting trastuzumab backbone conjugated to the maytansinoid DM1 via a non-cleavable SMCC linker. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ado-trastuzumab emtansine and therefore targets \u003cstrong\u003eHER2 (ERBB2)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eHER2 (ERBB2)\u003c\/strong\u003e. The molecule is a HER2-targeting trastuzumab backbone conjugated to the maytansinoid DM1 via a non-cleavable SMCC linker.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against HER2 (ERBB2); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of HER2 (ERBB2) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to HER2 (ERBB2).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface HER2 (ERBB2) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ado-trastuzumab emtansine.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAdo-trastuzumab emtansine\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eAntibody–drug conjugate (trastuzumab – DM1)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eHER2 (ERBB2)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ ADC\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of HER2 (ERBB2) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ado-trastuzumab emtansine drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962603885,"sku":"ab-131-ado-trastuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_1e7fe850-2547-4e11-a955-8af71e228405.jpg?v=1778728455"},{"product_id":"obinutuzumab-biosimilar-research-grade-bha18300167","title":"Obinutuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized, glycoengineered type II monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eObinutuzumab\u003c\/strong\u003e. Like the reference molecule, it binds a type II CD20 epitope, driving strong direct cell death and enhanced ADCC. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Obinutuzumab and therefore targets \u003cstrong\u003eCD20 (type II epitope)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD20 (type II epitope)\u003c\/strong\u003e. The molecule binds a type II CD20 epitope, driving strong direct cell death and enhanced ADCC.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD20 (type II epitope); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD20 (type II epitope) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD20 (type II epitope).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD20 (type II epitope) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Obinutuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eObinutuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized, glycoengineered type II monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD20 (type II epitope)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD20 (type II epitope) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Obinutuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962702189,"sku":"ab-131-obinutuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_4d2811c9-77e3-4cda-974f-de1e6cbebba4.jpg?v=1778728455"},{"product_id":"atezolizumab-biosimilar-research-grade-bha18300161","title":"Atezolizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized, Fc-engineered monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eAtezolizumab\u003c\/strong\u003e. Like the reference molecule, it binds PD-L1 and blocks its interaction with PD-1 and B7-1 (CD80). It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Atezolizumab and therefore targets \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePD-L1 (CD274)\u003c\/strong\u003e. The molecule binds PD-L1 and blocks its interaction with PD-1 and B7-1 (CD80).\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PD-L1 (CD274); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PD-L1 (CD274) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PD-L1 (CD274).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface PD-L1 (CD274) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Atezolizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAtezolizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized, Fc-engineered monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePD-L1 (CD274)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1 (N298A, aglycosylated)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PD-L1 (CD274) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Atezolizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962767725,"sku":"ab-131-atezolizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_fb37782f-0c3f-4090-98cc-ef6bc48589d0.jpg?v=1778728456"},{"product_id":"evolocumab-biosimilar-research-grade-bha18300165","title":"Evolocumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eEvolocumab\u003c\/strong\u003e. Like the reference molecule, it binds PCSK9 and prevents PCSK9-mediated LDL-receptor degradation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Evolocumab and therefore targets \u003cstrong\u003ePCSK9\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePCSK9\u003c\/strong\u003e. The molecule binds PCSK9 and prevents PCSK9-mediated LDL-receptor degradation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PCSK9; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PCSK9 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PCSK9.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Evolocumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eEvolocumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePCSK9\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG2\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PCSK9 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Evolocumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962800493,"sku":"ab-131-evolocumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_84367176-a7c0-498b-adf6-85bbb6fca68a.jpg?v=1778728455"},{"product_id":"aflibercept-biosimilar-research-grade-bha18300158","title":"Aflibercept Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eFc-fusion protein\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis research-grade reagent reproduces the target specificity of the reference biologic \u003cstrong\u003eAflibercept\u003c\/strong\u003e. It is a soluble decoy receptor (“VEGF trap”) that binds VEGF-A, VEGF-B and placental growth factor (PlGF) with high affinity. Supplied for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional control and assay standard.\u003c\/p\u003e\n  \u003cp\u003e\u003cstrong\u003eAflibercept\u003c\/strong\u003e is a fusion protein, not a monoclonal antibody; this product is the corresponding recombinant Fc-fusion protein and is provided as a research-grade equivalent.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eVEGF-A, VEGF-B and PlGF\u003c\/strong\u003e. The molecule is a soluble decoy receptor (“VEGF trap”) that binds VEGF-A, VEGF-B and placental growth factor (PlGF) with high affinity.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against VEGF-A, VEGF-B and PlGF; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of VEGF-A, VEGF-B and PlGF in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to VEGF-A, VEGF-B and PlGF.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Aflibercept.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eAflibercept\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eRecombinant Fc-fusion protein (VEGFR1 D2 + VEGFR2 D3 – human IgG1 Fc)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eVEGF-A, VEGF-B and PlGF\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003e— (not an antibody)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of VEGF-A, VEGF-B and PlGF binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Aflibercept drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962833261,"sku":"ab-131-aflibercept","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_bd89dacc-1336-489a-a7b2-d6d1f05280a7.jpg?v=1778728455"},{"product_id":"pembrolizumab-biosimilar-research-grade-bha18300170","title":"Pembrolizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003ePembrolizumab\u003c\/strong\u003e. Like the reference molecule, it binds PD-1 and blocks PD-L1\/PD-L2 engagement, restoring T-cell response. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Pembrolizumab and therefore targets \u003cstrong\u003ePD-1 (CD279)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003ePD-1 (CD279)\u003c\/strong\u003e. The molecule binds PD-1 and blocks PD-L1\/PD-L2 engagement, restoring T-cell response.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against PD-1 (CD279); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of PD-1 (CD279) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to PD-1 (CD279).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface PD-1 (CD279) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Pembrolizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003ePembrolizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003ePD-1 (CD279)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG4κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of PD-1 (CD279) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Pembrolizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327962931565,"sku":"ab-131-pembrolizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_0da435ab-0087-47a3-9400-c2bda02ca625.jpg?v=1778728457"},{"product_id":"nimotuzumab-biosimilar-research-grade-bha18300151","title":"Nimotuzumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eNimotuzumab\u003c\/strong\u003e. Like the reference molecule, it binds EGFR domain III and blocks ligand-induced receptor activation. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Nimotuzumab and therefore targets \u003cstrong\u003eEGFR\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eEGFR\u003c\/strong\u003e. The molecule binds EGFR domain III and blocks ligand-induced receptor activation.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against EGFR; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of EGFR in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to EGFR.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface EGFR on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Nimotuzumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eNimotuzumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of EGFR binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Nimotuzumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327963095405,"sku":"ab-131-nimotuzumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_02a13e84-ce70-402e-9384-7a8d42bc7dc9.jpg?v=1778728452"},{"product_id":"vedolizumab-biosimilar-research-grade-bha18300176","title":"Vedolizumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHumanized monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eVedolizumab\u003c\/strong\u003e. Like the reference molecule, it binds the α4β7 integrin and blocks its interaction with MAdCAM-1 (gut-selective). It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Vedolizumab and therefore targets \u003cstrong\u003eIntegrin α4β7\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eIntegrin α4β7\u003c\/strong\u003e. The molecule binds the α4β7 integrin and blocks its interaction with MAdCAM-1 (gut-selective).\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against Integrin α4β7; suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of Integrin α4β7 in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to Integrin α4β7.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface Integrin α4β7 on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Vedolizumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eVedolizumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHumanized monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eIntegrin α4β7\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of Integrin α4β7 binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Vedolizumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327963128173,"sku":"ab-131-vedolizumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_b70a68b8-b6eb-4bd5-9fba-cf7acbb154bb.jpg?v=1778728455"},{"product_id":"ofatumumab-biosimilar-research-grade-bha18300168","title":"Ofatumumab Biosimilar - Research Grade","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003cspan class=\"bhp-cat-pill\"\u003eHuman monoclonal antibody\u003c\/span\u003e\n\n  \u003ch2\u003eProduct Overview\u003c\/h2\u003e\n  \u003cp\u003eThis is a research-grade recombinant antibody that reproduces the antigen-binding specificity of the reference therapeutic \u003cstrong\u003eOfatumumab\u003c\/strong\u003e. Like the reference molecule, it binds a distinct membrane-proximal epitope on CD20 and induces potent complement-dependent cytotoxicity. It is intended for \u003cem\u003ein vitro\u003c\/em\u003e research use as a binding reagent, functional (blocking\/neutralizing) tool, and as a positive control or reference standard in bioanalytical assays.\u003c\/p\u003e\n  \u003cp\u003eThis product carries the same variable-region specificity as Ofatumumab and therefore targets \u003cstrong\u003eCD20 (membrane-proximal epitope)\u003c\/strong\u003e. It is a research reagent and is not the licensed therapeutic product.\u003c\/p\u003e\n\n  \u003ch2\u003eTarget \u0026amp; Mechanism\u003c\/h2\u003e\n  \u003cp\u003eTarget antigen: \u003cstrong\u003eCD20 (membrane-proximal epitope)\u003c\/strong\u003e. The molecule binds a distinct membrane-proximal epitope on CD20 and induces potent complement-dependent cytotoxicity.\u003c\/p\u003e\n\n  \u003ch2\u003eResearch Applications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eELISA (antigen binding)\u003c\/td\u003e\n\u003ctd\u003eUse as a binding reagent against CD20 (membrane-proximal epitope); suitable as a capture\/detection antibody and as an assay control.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLigand blocking \/ neutralization\u003c\/td\u003e\n\u003ctd\u003eFunctional blocking of CD20 (membrane-proximal epitope) in biochemical or cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBiophysics (SPR \/ BLI)\u003c\/td\u003e\n\u003ctd\u003eKinetic and affinity characterization of binding to CD20 (membrane-proximal epitope).\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFlow cytometry\u003c\/td\u003e\n\u003ctd\u003eDetection of cell-surface CD20 (membrane-proximal epitope) on relevant cell types.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003ePK \/ ADA assay control\u003c\/td\u003e\n\u003ctd\u003ePositive control or reference standard in pharmacokinetic (drug-level) and anti-drug-antibody (immunogenicity) assays for Ofatumumab.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eSpecifications\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eReference product\u003c\/th\u003e\n\u003ctd\u003eOfatumumab\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular format\u003c\/th\u003e\n\u003ctd\u003eHuman monoclonal antibody\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eTarget antigen\u003c\/th\u003e\n\u003ctd\u003eCD20 (membrane-proximal epitope)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eIsotype \/ class\u003c\/th\u003e\n\u003ctd\u003eIgG1κ\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eExpression\u003c\/th\u003e\n\u003ctd\u003eRecombinant, mammalian cell expression (see datasheet for lot details)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003ePurity \/ concentration \/ endotoxin\u003c\/th\u003e\n\u003ctd\u003eLot-specific — stated on the Certificate of Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003ctd\u003eSupplied in PBS, pH 7.0 (see datasheet)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-20°C long term; avoid repeated freeze–thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n\n  \u003ch2\u003eValidation \u0026amp; QC\u003c\/h2\u003e\n  \u003cp\u003e\u003cspan class=\"bhp-qc-badge\"\u003eCertificate of Analysis supplied per lot\u003c\/span\u003e\u003c\/p\u003e\n  \u003cp\u003eTypical release testing includes identity\/purity by SDS-PAGE and confirmation of CD20 (membrane-proximal epitope) binding by ELISA or SPR\/BLI. Full validation data and the product datasheet are available on request.\u003c\/p\u003e\n\n  \u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for diagnostic, therapeutic, or human\/animal \u003cem\u003ein vivo\u003c\/em\u003e use. Handle in accordance with good laboratory practice.\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003ch2\u003eRelated Products\u003c\/h2\u003e\n  \u003cp\u003ePair with the matching anti-idiotypic antibody and the Ofatumumab drug-level (PK) and anti-drug-antibody (ADA) ELISA kits for a complete bioanalytical workflow. Explore related antibodies, kits and reagents at \u003ca href=\"https:\/\/www.ebiohippo.com\" target=\"_blank\"\u003eBioHippo\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"AffinityImmuno Inc.","offers":[{"title":"500 ug","offer_id":53327963259245,"sku":"ab-131-ofatumumab","price":305.5,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/AffinityImmuno-Product-Antbodies-4_c4269442-f071-4d2c-bb6d-b32f380cfdc0.jpg?v=1778728454"},{"product_id":"anti-baffr-ianalumab-biosimilar-mab-bha18100045","title":"Anti-BAFFR (ianalumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting BAFF-R based on ianalumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eBAFF-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-BAFFR (ianalumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eBAFFR;TNFRSF13C;BAFF-R;BROMIX;CD268;CVID4;prolixin\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023224685,"sku":"BME100045-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328136470893,"sku":"BME100045-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100045-Anti-BAFFR-ianalumab-biosimilar-mAb-FLOW-Fig1-A.png?v=1782165298"},{"product_id":"anti-pd-1-pembrolizumab-biosimilar-mab-bha18100006","title":"Anti-PD-1 (pembrolizumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting PD-1 based on pembrolizumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003ePD-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-PD-1 (pembrolizumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003ePDCD1;PD1;CD279;SLEB2\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023257453,"sku":"BME100006-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134111597,"sku":"BME100006-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100006-Anti-PD-1-pembrolizumab-biosimilar-mAb-Elisa-fig1-1.png?v=1782165259"},{"product_id":"anti-b7-h3-enoblituzumab-biosimilar-mab-bha18100010","title":"Anti-B7-H3 (enoblituzumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting B7-H3 based on enoblituzumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eB7-H3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-B7-H3 (enoblituzumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eB7-H3;CD276;B7 homolog 3\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023290221,"sku":"BME100010-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134242669,"sku":"BME100010-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100010-Anti-B7-H3-enoblituzumab-biosimilar-mAb-Elisa-fig1-1.png?v=1782165467"},{"product_id":"anti-egfr-cetuximab-biosimilar-mab-bha18100034","title":"Anti-EGFR (Cetuximab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting EGFR based on Cetuximab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eChimeric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-EGFR (Cetuximab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eEGFR;ERBB;ERBB1;HER1;PIG61;mENA\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023322989,"sku":"BME100034-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328137322861,"sku":"BME100034-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100034-Anti-EGFR-mAbCetuximab-biosimilar-FLOW-Fig2.jpg?v=1782165237"},{"product_id":"anti-cd38-daratumumab-biosimilar-mab-bha18100004","title":"Anti-CD38 (daratumumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting CD38 based on daratumumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eCD38\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-CD38 (daratumumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD38;T10;ADPRC1\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023355757,"sku":"BME100004-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134570349,"sku":"BME100004-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100004-Anti-CD38-daratumumab-biosimilar-mAb-Elisa-fig1.png?v=1782165299"},{"product_id":"anti-tim3-cobolimab-biosimilar-mab-bha18100008","title":"Anti-TIM3 (cobolimab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting TIM3 based on cobolimab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eTIM3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-TIM3 (cobolimab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eHAVCR2;TIM3;TIMD3;FLJ14428;KIM3\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023388525,"sku":"BME100008-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328139026797,"sku":"BME100008-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100008-TIM3-Fig.2-FC-1.png?v=1782165257"},{"product_id":"anti-tnfsf11-denosumab-biosimilar-mab-bha18100057","title":"Anti-TNFSF11 (denosumab biosimilar)mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting TNFSF11 based on denosumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eTNFSF11\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-TNFSF11 (denosumab biosimilar)mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD254;hRANKL2;ODF;OPGL;OPTB2;RANKL;sOdf;TNLG6B;TRANCE\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023421293,"sku":"BME100058-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328136405357,"sku":"BME100058-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100058-Anti-TNFSF11-denosumab-biosimilarmAb-FLOW-Fig1.png?v=1782165242"},{"product_id":"anti-cd33-gemtuzumab-biosimilar-mab-bha18100015","title":"Anti-CD33 (gemtuzumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting CD33 based on gemtuzumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eCD33\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-CD33 (gemtuzumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD33;SIGLEC3;gp67\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023454061,"sku":"BME100015-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328137093485,"sku":"BME100015-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100015-Anti-CD33gemtuzumab-ozogamicin-biosimilar-mAb-FLOW-Fig1-A.png?v=1782165303"},{"product_id":"anti-icos-vopratelimab-biosimilar-mab-bha18100012","title":"Anti-ICOS (vopratelimab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting ICOS based on vopratelimab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eICOS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-ICOS (vopratelimab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eICOS;CD278;AILIM;Inducible T-cell costimulator\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023486829,"sku":"BME100012-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134046061,"sku":"BME100012-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100012-Anti-ICOS-vopratelimab-biosimilar-mAb-Elisa-fig1.png?v=1782165249"},{"product_id":"anti-cd40-ligand-ruplizumab-biosimilar-mab-bha18100042","title":"Anti-CD40 Ligand (ruplizumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting CD40 Ligand based on ruplizumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eCD40 Ligand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-CD40L (ruplizumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD40LG;CD154;CD40L;HIGM1;IGM;IMD3;T-BAM;TNFSF5;TRAP;gp39\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023519597,"sku":"BME100042-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328136536429,"sku":"BME100042-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100042-Anti-CD40L-ruplizumab-biosimilar-mAb-FLOW-Fig1-A.png?v=1782165246"},{"product_id":"anti-tigit-tiragolumab-biosimilar-mab-bha18100026","title":"Anti-TIGIT (tiragolumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting TIGIT based on tiragolumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eTIGIT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-TIGIT (tiragolumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eTIGIT;SIG9;STM3\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023617901,"sku":"BME100026-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328139911533,"sku":"BME100026-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100026-BM77-2-FAC-TransfectedWithTIGIT-Fig2.jpg?v=1782165307"},{"product_id":"anti-il17ra-brodalumab-biosimilar-mab-bha18100038","title":"Anti-IL17RA (brodalumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting IL17RA based on brodalumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eIL17RA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-IL17RA (brodalumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD217;CDw217;IL-17RA;IL17R;CANDF5;hIL-17R\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023650669,"sku":"BME100038-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134930797,"sku":"BME100038-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100038-Anti-IL17RA-brodalumab-biosimilar-mAb-FLOW-Fig1-A.png?v=1782165240"},{"product_id":"anti-m-csf-lacnotuzumab-biosimilar-mab-bha18100093","title":"Anti-M-CSF(lacnotuzumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting M-CSF based on lacnotuzumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eM-CSF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-M-CSF(lacnotuzumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCSF-1;MCSF\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023716205,"sku":"BME100104-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328135192941,"sku":"BME100104-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100104-BM144-Anti-M-CSF-FACS-Fig1.jpg?v=1782165438"},{"product_id":"anti-cd27-varlilumab-biosimilar-mab-bha18100018","title":"Anti-CD27 (varlilumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting CD27 based on varlilumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eCD27\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-CD27 (varlilumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD27;TNFRSF7;S152;T14;Tp55\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023781741,"sku":"BME100018-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134373741,"sku":"BME100018-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100018-Anti-CD27-varlilumab-biosimilar-mAb-FLOW-Fig3-A.jpg?v=1782165248"},{"product_id":"anti-cd138-indatuximab-biosimilar-mab-bha18100014","title":"Anti-CD138 (indatuximab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting CD138 based on indatuximab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eCD138\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eChimeric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-CD138 (indatuximab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eSDC1;Syndecan-1;CD138;SYND1;SDC\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023814509,"sku":"BME100014-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134177133,"sku":"BME100014-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100014-Anti-CD138indatuximab-ravtansine-biosimilar-mAb-FLOW-Fig1-A.png?v=1782165301"},{"product_id":"anti-cd70-vorsetuzumab-biosimilar-mab-bha18100005","title":"Anti-CD70 (vorsetuzumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting CD70 based on vorsetuzumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eCD70\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-CD70 (vorsetuzumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eCD70;CD27L;CD27LG;TNFSF7\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023847277,"sku":"BME100005-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328134439277,"sku":"BME100005-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100005-Anti-CD70-vorsetuzumab-biosimilar-mAb-Elisa-fig1.png?v=1782165243"},{"product_id":"anti-dll3-rovalpituzumab-biosimilar-mab-bha18100065","title":"Anti-DLL3(Rovalpituzumab biosimilar) mAb","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-qc-badge{display:inline-block;background:#e6f4ea;color:#1a7a3c;border:1px solid #a8d5b5;border-radius:4px;padding:6px 14px;font-size:14px;font-weight:600}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n.bhp-desc .bhp-biosim-note{background:#e8f0fb;border-left:4px solid #003366;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0;font-size:14px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cspan class=\"bhp-cat-pill\"\u003eBiosimilar Antibody\u003c\/span\u003e\n\u003cp\u003eResearch-grade biosimilar monoclonal antibody targeting DLL3 based on Rovalpituzumab. Produced for in vitro research purposes only. Not for therapeutic or diagnostic use.\u003c\/p\u003e\n\u003cdiv class=\"bhp-biosim-note\"\u003e\n\u003cstrong\u003eResearch Use Only:\u003c\/strong\u003e This is a research-grade biosimilar antibody. It shares structural and functional characteristics with the reference biologic but is produced for in vitro research applications only. Not for use in therapeutic or diagnostic procedures.\u003c\/div\u003e\n\u003ch2\u003eValidated Applications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eApplication\u003c\/th\u003e\n\u003cth\u003eRecommended Dilution\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eELISA\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFlow Cytometry (FC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA 1:5000-10000; Flow Cyt 1:100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cspan class=\"bhp-qc-badge\"\u003e✔ Quality-Verified | DIMA Biotechnology\u003c\/span\u003e\n\u003ch2\u003eAntibody Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003ctd\u003eDLL3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eHost\u003c\/th\u003e\n\u003ctd\u003eHumanized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eClonality\u003c\/th\u003e\n\u003ctd\u003eMonoclonal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIsotype\u003c\/th\u003e\n\u003ctd\u003eIgG1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eConjugate\u003c\/th\u003e\n\u003ctd\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReactivity\u003c\/th\u003e\n\u003ctd\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurification\u003c\/th\u003e\n\u003ctd\u003eAffinity Purification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Description\u003c\/th\u003e\n\u003ctd\u003eAnti-DLL3(Rovalpituzumab biosimilar) mAb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eStore at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003ctd\u003e12 months from date of dispatch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eLyophilized antibodies are shipped at ambient temperature\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAlternative Names \/ Aliases\u003c\/h2\u003e\n\u003cp style=\"color:#555\"\u003eSCDO1\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003e⚠ Research Use Only (RUO).\u003c\/strong\u003e Not approved for therapeutic or diagnostic use in humans or animals. This biosimilar antibody is strictly for in vitro research purposes. Handle with standard laboratory precautions.\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DIMA Biotechnology","offers":[{"title":"50 ug","offer_id":53328023880045,"sku":"BME100068-50UG","price":82.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53328139190637,"sku":"BME100068-100UG","price":162.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BME100068-BM50-flow-DLL3.png?v=1782165246"}],"url":"https:\/\/www.ebiohippo.com\/collections\/biosimilar-antibodies.oembed?page=20","provider":"BioHippo","version":"1.0","type":"link"}